In summary, the present study showed that HK2 suppression could lessen HNSCC oncogenicity and modulate therapeutic sensitivity, thereby being an ideal therapeutic target for HNSCCs. This evidence concerns the gene HK2 and head and neck squamous cell carcinoma.